U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H25FN2O3
Molecular Weight 359.425
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of FLORBETAPIR F-18

SMILES

CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCC[18F])N=C2)C=C1

InChI

InChIKey=YNDIAUKFXKEXSV-CRYLGTRXSA-N
InChI=1S/C20H25FN2O3/c1-22-19-7-4-17(5-8-19)2-3-18-6-9-20(23-16-18)26-15-14-25-13-12-24-11-10-21/h2-9,16,22H,10-15H2,1H3/b3-2+/i21-1

HIDE SMILES / InChI

Molecular Formula C20H25FN2O3
Molecular Weight 359.425
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including, https://investor.lilly.com/releasedetail2.cfm?ReleaseID=662647

Florbetapir (18F) (trade name AMYViD; also known as florbetapir-fluorine-18 or 18F-AV-45) is a PET scanning radiopharmaceutical compound containing the radionuclide fluorine-18, recently FDA approved as a diagnostic tool for Alzheimer's disease. Florbetapir, like Pittsburgh compound B (PiB), binds to beta-amyloid, however fluorine-18 has a half-life of 110 minutes, in contrast to PiB's radioactive half life of 20 minutes. Wong et al. found that the longer life allowed the tracer to accumulate significantly more in the brains of people with AD, particularly in the regions known to be associated with beta-amyloid deposits. A negative Amyvid scan indicates sparse to no neuritic plaques, and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvidis an adjunct to other diagnostic evaluations

CNS Activity

Curator's Comment: lorbetapir F 18 diffuses across the human blood-brain barrier and produces a radioactivity signal detectable throughout the brain

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.7 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Amyvid

Approved Use

Used as a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.

Launch Date

2012
PubMed

PubMed

TitleDatePubMed
¹⁸F-labeled 2-phenylquinoxaline derivatives as potential positron emission tomography probes for in vivo imaging of β-amyloid plaques.
2012 Nov
¹⁸F-labeled 2-phenylquinoxaline derivatives as potential positron emission tomography probes for in vivo imaging of β-amyloid plaques.
2012 Nov
Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
2014 Oct
Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
2014 Oct
Patents

Sample Use Guides

Administer 370 MBq (10 mCi) as a single intravenous bolus in a total volume of 10 mL or less
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:29:50 GMT 2023
Edited
by admin
on Sat Dec 16 17:29:50 GMT 2023
Record UNII
6W15Z5R0RU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLORBETAPIR F-18
ORANGE BOOK   USAN  
USAN  
Official Name English
florbetapir (¹⁸F) [INN]
Common Name English
FLORBETAPIR(18-F)
Common Name English
FLORBETAPIR F 18
MI  
Common Name English
AV45 F-18
Common Name English
18F-AV45
Common Name English
AMYVID
Brand Name English
FLORBETAPIR F-18 [USAN]
Common Name English
Florbetapir (18f) [WHO-DD]
Common Name English
4-((1E)-2-(6-(2-(2-(2-(18F)FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N- METHYLBENZENAMINE
Common Name English
FLORBETAPIR (18F)
EMA EPAR   INN   WHO-DD  
INN  
Official Name English
FLORBETAPIR, F-18
Common Name English
18F-AV-45
Code English
FLORBETAPIR F-18 [ORANGE BOOK]
Common Name English
FLORBETAPIR (18F) [EMA EPAR]
Common Name English
AV-45 F-18
Code English
FLORBETAPIR F 18 [MI]
Common Name English
(18F)AV-45
Code English
BENZENAMINE, 4-((1E)-2-(6-(2-(2-(2-(FLUORO-18F)ETHOXY)ETHOXY)ETHOXY)-3- PYRIDINYL)ETHENYL)-N- METHYL-
Common Name English
Classification Tree Code System Code
WHO-ATC V09AX05
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
NDF-RT N0000177914
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
EMA ASSESSMENT REPORTS AMYVID (AUTHORIZED: RADIONUCLIDE IMAGING)
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
NDF-RT N0000175871
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
WHO-VATC QV09AX05
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
Code System Code Type Description
INN
9193
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
NDF-RT
N0000175869
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY Positron Emitting Activity [MoA]
DRUG CENTRAL
4285
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
LACTMED
Florbetapir F 18
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
EVMPD
SUB33779
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
USAN
WW-07
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
DRUG BANK
DB09149
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
FDA UNII
6W15Z5R0RU
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
CHEBI
66880
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
NCI_THESAURUS
C171884
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
MESH
C545186
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
WIKIPEDIA
Florbetapir_(18F)
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
ChEMBL
CHEMBL1908919
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
EPA CompTox
DTXSID80241898
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
MERCK INDEX
m5410
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY Merck Index
CAS
956103-76-7
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
DAILYMED
6W15Z5R0RU
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
PUBCHEM
24822371
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
SMS_ID
100000127658
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY
RXCUI
1427224
Created by admin on Sat Dec 16 17:29:51 GMT 2023 , Edited by admin on Sat Dec 16 17:29:51 GMT 2023
PRIMARY RxNorm
Related Record Type Details
TARGET->RADIOLIGAND
Related Record Type Details
METABOLITE -> PARENT
The metabolites have shown lower uptake in the brain and lower affinity for binding to beta amyloid thus, it is concluded that there will be minimal interference from the metabolites to the PET image from 18F-AV-45 in the brain.
METABOLITE INACTIVE -> PARENT
IN-VIVO
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC